Resist composition and patterning process
US-2017351177-A1 · Dec 7, 2017 · US
Phenothiazine diaminium salts and their use
US9283230B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9283230-B2 |
| Application number | US-201113984841-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 15, 2011 |
| Priority date | Feb 11, 2011 |
| Publication date | Mar 15, 2016 |
| Grant date | Mar 15, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to compounds of general formula (I): wherein: each of R 1 and R 9 is independently selected from: —H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; each of R 3NA and R 3NB is independently selected from: —H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; each of R7NA and R7NB is independently selected from: —H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; and wherein: each of R A and R B is independently selected from: C 1-4 alkyl, halogenated C 1-4 alkyl, and C 6-10 aryl; or R A and R B are linked to form a group selected from: C 1-6 alkylene and C 6-10 arylene; and pharmaceutically acceptable salts thereof, which are useful in the treatment of, for example, Alzheimer's disease. In other aspects the invention also relates to novel formulations of 3,7-diamino-10H-phenothiazinium salts.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a tauopathy comprising administering to a subject in need thereof the compound of the following formula: or a pharmaceutically acceptable salt, solvate, or hydrate thereof. 2. The method of claim 1 , wherein the tauopathy is Alzheimer's disease (AD), Pick's disease, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), FTD with parkinsonism linked to chromosome 17 (FTDP 17), frontotemporal lobar degeneration (FTLD) syndromes; disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC), pallido-ponto-nigral degeneration (PPND), Guam-ALS syndrome, pallido nigro luysian degeneration (PNLD), cortico-basal degeneration (CBD), dementia with argyrophilic grains (AgD), dementia pugilistica (DP) or chronic traumatic encephalopathy (CTE), Down's syndrome (DS), dementia with Lewy bodies (DLB), subacute sclerosing panencephalitis (SSPE), Niemann-Pick disease, type C (NPC), Sanfilippo syndrome type B, mucopolysaccharidosis III B (MPS III B)), or myotonic dystrophies (DM), DM1 or DM2. 3. The method of claim 2 , wherein the tauopathy is Alzheimer's disease. 4. The method of claim 2 , wherein the tauopathy is PSP. 5. The method of claim 2 , wherein the tauopathy is FTD, FTDP-17, or FTLD.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the nervous system · CPC title
Anti-Parkinson drugs · CPC title
for HIV · CPC title
for treating abnormal movements, e.g. chorea, dyskinesia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9283230B2 cover?
- The invention relates to compounds of general formula (I): wherein: each of R 1 and R 9 is independently selected from: —H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; each of R 3NA and R 3NB is independently selected from: —H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; each of R7NA and R7NB is independently selected from: —H, C 1-4 alkyl, C 2-4 alkenyl, and halog…
- Who is the assignee on this patent?
- Clunas Scott, Storey John Mervyn David, Sinclair James Peter, and 13 more
- What technology area does this patent fall under?
- Primary CPC classification C07D279/20. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).